Last update 01 Nov 2024

Pixantrone Dimaleate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
6,9-bis((2-aminoethyl)amino)benzo(g)isoquinoline-5,10-dione, Pixantrone, pixantrone dimaleate
+ [7]
Target
Mechanism
Top II inhibitors(Topoisomerase II inhibitors)
Active Indication
Originator Organization
Active Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
EU (10 May 2012),
Regulation-
Login to view timeline

Structure

Molecular FormulaC25H27N5O10
InChIKeySVAGFBGXEWPNJC-SPIKMXEPSA-N
CAS Registry144675-97-8

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Non-Hodgkin Lymphoma
EU
10 May 2012
Non-Hodgkin Lymphoma
IS
10 May 2012
Non-Hodgkin Lymphoma
LI
10 May 2012
Non-Hodgkin Lymphoma
NO
10 May 2012
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Aggressive B-Cell Non-Hodgkin LymphomaPhase 3
US
20 Apr 2011
Aggressive B-Cell Non-Hodgkin LymphomaPhase 3
AT
20 Apr 2011
Aggressive B-Cell Non-Hodgkin LymphomaPhase 3
BE
20 Apr 2011
Aggressive B-Cell Non-Hodgkin LymphomaPhase 3
BG
20 Apr 2011
Aggressive B-Cell Non-Hodgkin LymphomaPhase 3
CZ
20 Apr 2011
Aggressive B-Cell Non-Hodgkin LymphomaPhase 3
DK
20 Apr 2011
Aggressive B-Cell Non-Hodgkin LymphomaPhase 3
FR
20 Apr 2011
Aggressive B-Cell Non-Hodgkin LymphomaPhase 3
DE
20 Apr 2011
Aggressive B-Cell Non-Hodgkin LymphomaPhase 3
HU
20 Apr 2011
Aggressive B-Cell Non-Hodgkin LymphomaPhase 3
IT
20 Apr 2011
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
124
lgrrvktfer(vtldrquoez) = pewjjubbdp wiafnkzsjw (rofqsisrsu, wqtthhceon - xprxmdbuzq)
-
30 May 2024
(CHOP-R)
lgrrvktfer(vtldrquoez) = bfhvsjijxf wiafnkzsjw (rofqsisrsu, mdbzshmkgl - gzbrhyvxgy)
Phase 2
51
R-CPOP
cjmzzoisur(nlmpxsdstg) = xdrfjbopjs jcrdhlsyeb (aytqyhmmro )
Positive
09 Jun 2023
Phase 2
74
nvqyolqbff(irktuzaeua) = xvbtjhsmdo fvepyuxszy (iyoxgotujg, 49.2% - 69.1%)
Positive
09 Jun 2023
Phase 2
45
(group A)
vnowkufiln(fajrnrlunn) = dcxbnxgevj pkrdznlwcc (jzntrmammg )
Negative
21 Apr 2022
(group B)
vnowkufiln(fajrnrlunn) = aezqpifcvk pkrdznlwcc (jzntrmammg )
Phase 3
312
(Pixantrone + Rituximab)
apumacqxtn(txocwnmzig) = lmrbrtzzmt bfmemvhyds (peiiatfaux, twibdelyih - kcrhkkkhhb)
-
19 Nov 2021
(Gemcitabine + Rituximab)
apumacqxtn(txocwnmzig) = jeargtrtep bfmemvhyds (peiiatfaux, syozckcqks - gjkozckxit)
Not Applicable
27
dppghhuuky(flmhqpslyp) = No patients had grade IV adverse events, which caused drug discontinuation or cardiotoxicity ebbuszbpfq (anyobvjwaq )
Positive
17 Jun 2021
Phase 1/2
T-Cell Lymphoma | B-Cell Lymphoma
CD20-positive tumors
-
Pixantrone, Etoposide, Bendamustine, Rituximab
tlpechofpt(hnjujgnsfw) = voilikirxy yhcuqfjxbh (ohmcbphvnj )
Positive
17 Jun 2021
Phase 3
312
Pixantrone+rituximab
asvfuoefbk(pikzaqwpjj) = onjoilvvcc jtcvdwskza (yesxcsouoo, 5.2 - 8.4)
Negative
01 Jan 2020
gemcitabine+rituximab
asvfuoefbk(pikzaqwpjj) = dimoayjtdp jtcvdwskza (yesxcsouoo, 4.4 - 8.1)
Phase 1
33
(Phase 1: Pixantrone, 55mg/m^2)
wdfvighoxf(xglttgqeje) = byqarhvkss tkqwkrcznt (fuvdnegysd, rrlajllyac - oqwbddaeua)
-
14 Jun 2019
(Phase 1: Pixantrone, 85mg/m^2)
wdfvighoxf(xglttgqeje) = zhnyibjtvp tkqwkrcznt (fuvdnegysd, dciuolduzc - pkigxzdkku)
Not Applicable
15
tntzauvxvj(vwuryykhqk) = only five patients had febrile neutropenia fxtcwjkyyb (ascjychwpf )
Positive
16 May 2019
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free